Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials.

A key principle for interpretation of subgroup results is that quantitative interactions (differences in degree) are much more likely than qualitative interactions (differences in kind). Quantitative interactions are likely to be truly present whether or not they are apparent, whereas apparent qualitative interactions should generally be disbelieved as they have usually not been replicated consistently. Therefore, the overall trial result is usually a better guide to the direction of effect in subgroups than the apparent effect observed within a subgroup. Failure to specify prior hypotheses, to account for multiple comparisons, or to correct P values increases the chance of finding spurious subgroup effects. Conversely, inadequate sample size, classification of patients into the wrong subgroup, and low power of tests of interaction make finding true subgroup effects difficult. We recommend examining the architecture of the entire set of subgroups within a trial, analyzing similar subgroups across independent trials, and interpreting the evidence in the context of known biologic mechanisms and patient prognosis.

[1]  Salim Yusuf,et al.  Studies of left ventricular dysfunction (SOLVD)--rationale, design and methods: two trials that evaluate the effect of enalapril in patients with reduced ejection fraction. , 1990, The American journal of cardiology.

[2]  R Collins,et al.  Avoidance of large biases and large random errors in the assessment of moderate treatment effects: the need for systematic overviews. , 1987, Statistics in medicine.

[3]  L. Wilhelmsen,et al.  Reduction of sudden deaths after myocardial infarction by treatment with alprenolol. Preliminary results. , 1974, Lancet.

[4]  S. Yusuf,et al.  Routine medical management of acute myocardial infarction. Lessons from overviews of recent randomized controlled trials. , 1990, Circulation.

[5]  K. Swedberg,et al.  EFFECT ON MORTALITY OF METOPROLOL IN ACUTE MYOCARDIAL INFARCTION A Double-blind Randomised Trial , 1981, The Lancet.

[6]  C. Furberg,et al.  THERAPY AND PREVENTION , 2005 .

[7]  J. Wittes,et al.  Overview of results of randomized clinical trials in heart disease. II. Unstable angina, heart failure, primary prevention with aspirin, and risk factor modification. , 1988, JAMA.

[8]  R. Wittes,et al.  Methodologic guidelines for reports of clinical trials. , 1985, Cancer treatment reports.

[9]  J. Wittes,et al.  Overview of results of randomized clinical trials in heart disease. I. Treatments following myocardial infarction. , 1988, JAMA.

[10]  C. E. Davis,et al.  Empirical Bayes estimates of subgroup effects in clinical trials. , 1990, Controlled clinical trials.

[11]  Jack Cuzick,et al.  Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women , 1988 .

[12]  K. K. Lan,et al.  Stochastically curtailed tests in long–term clinical trials , 1982 .

[13]  Medical Classic. (Book Reviews: An Introduction to the Study of Experimental Medicine) , 1950 .

[14]  R. Peto,et al.  Beta blockade during and after myocardial infarction: an overview of the randomized trials. , 1985, Progress in cardiovascular diseases.

[15]  J. Wittes,et al.  Surrogate endpoints in clinical trials: cardiovascular diseases. , 1989, Statistics in medicine.

[16]  M. Walsh,et al.  Practolol in acute myocardial infarction. , 2009, Acta medica Scandinavica. Supplementum.

[17]  Rupert G. Miller Simultaneous Statistical Inference , 1966 .

[18]  K. K. Lan,et al.  Discrete sequential boundaries for clinical trials , 1983 .

[19]  S. Yusuf,et al.  Selection of patients for randomized controlled trials: implications of wide or narrow eligibility criteria. , 1990, Statistics in medicine.

[20]  A. M. Skene,et al.  TRIAL OF TISSUE PLASMINOGEN ACTIVATOR FOR MORTALITY REDUCTION IN ACUTE MYOCARDIAL INFARCTION Anglo-Scandinavian Study of Early Thrombolysis (ASSET) , 1988, The Lancet.

[21]  G. Sutton,et al.  A long-term prevention study with oxprenolol in coronary heart disease. , 1982, The New England journal of medicine.

[22]  F. Pedersen,et al.  EFFECT OF ALPRENOLOL ON MORTALITY AMONG PATIENTS WITH DEFINITE OR SUSPECTED ACUTE MYOCARDIAL INFARCTION Preliminary Results , 1979, The Lancet.

[23]  J D Knoke,et al.  Estimating baseline values of the variable of intervention in a clinical trial. , 1985, Controlled clinical trials.

[24]  R. Simon,et al.  Patient subsets and variation in therapeutic efficacy. , 1982, British journal of clinical pharmacology.